NCT05895201 2024-04-29
High-Dose Post-Transplant Cyclophosphamide, Bortezomib, and Sitagliptin for the Prevention of GVHD
Indiana University
Phase 1/2 Withdrawn
Clinical Trials
8 trialsNCT03701321 2023-09-26
Daratumumab, Bortezomib, and Dexamethasone With or Without Venetoclax in Treating Patients With Relapsed or Refractory Multiple Myeloma
National Cancer Institute (NCI)
Phase 1/2 Withdrawn
NCT05408026 2023-01-27
Study of Combination POM, BTZ, Low-Dose DEX, and DARA (PVD-DARA) in Patients With RRMM
Alliance Foundation Trials, LLC.
Phase 1/2 Withdrawn
NCT00995059 2023-01-05
Bortezomib Before Donor Stem Cell Transplant in Treating Patients With Multiple Myeloma
Mayo Clinic
Phase 1/2 Withdrawn
NCT02605356 2016-10-07
Phase 1b/2 Study Testing Radium-223 Dichloride/Bortezomib/Dexamethasone Combination in Relapsed Multiple Myeloma
Bayer
Phase 1/2 Withdrawn
NCT00516191 2015-03-04
DMV
University of California, San Francisco
Phase 1/2 Withdrawn
NCT00313690 2014-05-21
Cancer Treatment Followed by Surgery for Early Stage Non-small Cell Lung Cancer
University of Southern California
Phase 1/2 Withdrawn
NCT00411593 2012-02-08
Phase I-II for Patients With Recurrent or Refractory Non-small Cell Lung Cancer (NSCLC)
M.D. Anderson Cancer Center
Phase 1/2 Withdrawn